MAP2K1

Across TCGA pan-cancer cohorts, MAP2K1 mass-spec protein differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of MAP2K1’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where MAP2K1 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types MAP2K1 is over-expressed in tumor, although a few such as COAD show the opposite, repressed pattern.

CCRCC, COAD, and LSCC are the cancer types where MAP2K1 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MAP2K1 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Female	All	+0.293	<.001	10	view →
COAD	Male	III,IV	−0.286	<.001	8	view →
LSCC	Female	III,IV	+0.237	.007	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

MAP2K1–CCRCC

Open the CCRCC breakdown →